The management of cytomegalovirus (CMV) infection or disease in transplant patients has historically been challenging due to side effects with older antiviral therapies, including myelotoxicity and renal toxicity. Side effect and efficacy data for newer improved transplant antiviral therapies, including maribavir and letermovir, is emerging rapidly. The goal of this activity is to help you learn about the emerging data and how to apply it in clinical practice when managing your transplant patients.
Upon completion of this activity, participants should be better able to:
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States
Professor, Department of Medicine
University of Toronto
R. Fraser Elliott Chair, Transplantation
University Health Network
Director, University of Toronto Transplant Institute
Toronto, Ontario, Canada
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
